# Emergent BioSolutions Inc.: overview

EBS · NYSE · CIK 1367644 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ebs.md) · [Financials](/companies/ebs/financials.md) · [Filings](/companies/ebs/filings.md) · [Insiders](/companies/ebs/insiders.md)

Latest reported revenue: [$234.3m](/filings/0001367644-26-000082.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001367644-26-000082).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [294](/filings/0001367644-25-000202.md) | [195 d](/filings/0001367644-26-000015.md) | [222](/filings/0001367644-26-000065.md) | [141](/filings/0001367644-26-000082.md) | [231](/filings/0001367644-25-000202.md) | [149 d](/filings/0001367644-26-000015.md) | [156](/filings/0001367644-26-000065.md) | [234](/filings/0001367644-26-000082.md) |
| Gross margin | % | [54.9%](/filings/0001367644-24-000178.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [22.0%](/filings/0001367644-25-000202.md) | [(4.9%) d](/filings/0001367644-26-000015.md) | [22.5%](/filings/0001367644-26-000065.md) | [1.1%](/filings/0001367644-26-000082.md) | [33.1%](/filings/0001367644-25-000202.md) | [(18.8%) d](/filings/0001367644-26-000015.md) | [6.7%](/filings/0001367644-26-000065.md) | [(53.4%)](/filings/0001367644-26-000082.md) |
| Net margin | % | [39.1%](/filings/0001367644-25-000202.md) | [(16.1%) d](/filings/0001367644-26-000015.md) | [30.6%](/filings/0001367644-26-000082.md) | [(8.5%)](/filings/0001367644-26-000082.md) | [22.2%](/filings/0001367644-25-000202.md) | [(36.7%) d](/filings/0001367644-26-000015.md) | [4.4%](/filings/0001367644-26-000082.md) | [(76.9%)](/filings/0001367644-26-000082.md) |
| Diluted EPS | $ per share | [2.06](/filings/0001367644-25-000202.md) | not reported | [1.19](/filings/0001367644-26-000065.md) | [(0.22)](/filings/0001367644-26-000082.md) | [0.91](/filings/0001367644-25-000202.md) | not reported | [0.07](/filings/0001367644-26-000065.md) | [(3.49)](/filings/0001367644-26-000082.md) |
| Free cash flow | $m | [148 d](/filings/0001367644-25-000202.md) | [(81.6) d](/filings/0001367644-26-000015.md) | [(14.8)](/filings/0001367644-26-000065.md) | [104 d](/filings/0001367644-26-000082.md) | [(5.7) d](/filings/0001367644-25-000202.md) | [73.8 d](/filings/0001367644-26-000015.md) | [(36.2)](/filings/0001367644-26-000065.md) | [54.0 d](/filings/0001367644-26-000082.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,774](/filings/0001367644-24-000033.md) | [1,118](/filings/0001367644-25-000021.md) | [1,049](/filings/0001367644-26-000015.md) | [1,044](/filings/0001367644-26-000015.md) | [743](/filings/0001367644-26-000015.md) |
| Gross margin | % | [50.3%](/filings/0001367644-24-000033.md) | [34.3%](/filings/0001367644-24-000033.md) | [30.3%](/filings/0001367644-24-000033.md) | not reported | not reported |
| Operating margin | % | [19.2%](/filings/0001367644-24-000033.md) | [(15.2%)](/filings/0001367644-25-000021.md) | [(69.2%)](/filings/0001367644-26-000015.md) | [(10.4%)](/filings/0001367644-26-000015.md) | [13.5%](/filings/0001367644-26-000015.md) |
| Net margin | % | [12.4%](/filings/0001367644-24-000033.md) | [(18.9%)](/filings/0001367644-25-000021.md) | [(72.5%)](/filings/0001367644-26-000015.md) | [(18.3%)](/filings/0001367644-26-000015.md) | [7.1%](/filings/0001367644-26-000015.md) |
| Diluted EPS | $ per share | [4.06](/filings/0001367644-24-000033.md) | [(4.22)](/filings/0001367644-25-000021.md) | [(14.85)](/filings/0001367644-26-000015.md) | [(3.60)](/filings/0001367644-26-000015.md) | [0.93](/filings/0001367644-26-000015.md) |
| Free cash flow | $m | [96.1](/filings/0001367644-24-000033.md) | [(150)](/filings/0001367644-25-000021.md) | [(258)](/filings/0001367644-26-000015.md) | [35.8](/filings/0001367644-26-000015.md) | [157](/filings/0001367644-26-000015.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ebs/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $39.5m | 4,716,599 |  | Added +375,137 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $25.8m | 3,076,646 |  | Added +319,488 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $24.6m | 2,929,238 |  | Added +79,537 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $23.2m | 2,770,448 |  | Added +344,726 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $18.4m | 2,198,839 |  | Reduced −59,156 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $11.2m | 1,337,243 |  | Added +64,334 |
| [CHARLES SCHWAB INVESTMENT MANAGEMENT INC](/funds/884546.md) | 2026-06-30 | $10.1m | 1,200,791 |  | Reduced −305,284 |
| [OAK HILL ADVISORS LP](/funds/1164688.md) | 2026-06-30 | $9.3m | 1,113,338 |  | Unchanged |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $9.0m | 1,072,185 |  | Added +540,184 |
| [Ancora Advisors LLC](/funds/1446114.md) | 2026-06-30 | $8.9m | 1,067,867 |  | Added +658,600 |

## Recent filings

[All 1,415 filings](/companies/ebs/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-16 | 11:48 ET | [8-K](/filings/0001367644-26-000098.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001367644-26-000098 |
| 2026-09-14 | 20:02 ET | [8-K](/filings/0001367644-26-000091.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001367644-26-000091 |
| 2026-09-01 | 20:13 ET | [8-K](/filings/0001367644-26-000088.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001367644-26-000088 |
| 2026-08-06 | 21:47 ET | [10-Q](/filings/0001367644-26-000082.md) | Quarterly report, period 2026-06-30 | 0001367644-26-000082 |
| 2026-08-05 | 20:06 ET | [8-K](/filings/0001367644-26-000080.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001367644-26-000080 |
| 2026-06-29 | 15:14 ET | [8-K](/filings/0001367644-26-000068.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001367644-26-000068 |
| 2026-05-01 | 21:54 ET | [10-Q](/filings/0001367644-26-000065.md) | Quarterly report, period 2026-03-31 | 0001367644-26-000065 |
| 2026-04-30 | 20:32 ET | [8-K](/filings/0001367644-26-000059.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001367644-26-000059 |
| 2026-04-30 | 11:30 ET | [8-K](/filings/0001367644-26-000051.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001367644-26-000051 |
| 2026-04-17 | 21:51 ET | [8-K](/filings/0001367644-26-000038.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001367644-26-000038 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001367644-26-000015.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/65276c04-6208-41c5-a084-b5e521845d3c)

## About the filer

- CIK: 1367644
- Tickers: EBS
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.